I 1998 modtog EMEA et stigende antal indberetninger om tilfælde uden for EU af formodede alvorlige uventede bivirkninger ved centralt godkendte produkter.
In 1998 the EMEA was notified of an increasing number of reports of suspected serious unexpected adverse drug reactions occurring outside the EU for centrally authorised products.